Porphyria Cutanea Tarda Clinical Trial
OBJECTIVES: I. Determine the effect of standard treatments on various predisposing factors
in patients with porphyria cutanea tarda (PCT).
II. Investigate alcohol history, smoking, liver dysfunction and its etiology, estrogen use,
and family history of PCT in these patients.
III. Study the relationships of excess iron and the hemochromatosis gene to PCT, including
clinical features and risk of recurrence in these patients.
IV. Assess hepatitis C virus infections in these patients. V. Assess vitamin C levels in
these patients before and after treatment. VI. Assess dietary habits in these patients. VII.
Assess activity of cytochrome P450 enzymes (CYP) in vivo in these patients.
VIII. Study polymorphic genes for enzymes that metabolize foreign chemicals, including CYP
enzymes and glutathione transferases in these patients.
PROTOCOL OUTLINE: Patients undergo a complete medical evaluation and documentation of
porphyria cutanea tarda (PCT) including history, physical examination, standard clinical
laboratory tests and porphyrin studies. Alcohol history, smoking, liver dysfunction and its
etiology, estrogen use, and family history of PCT are investigated and recorded. Patients
complete a questionnaire to assess intake of vitamin C and other nutrients.
Iron status is assessed by serum ferritin, Fe and Fe binding capacity, and by the number of
phlebotomies needed to reduce ferritin to the target level. A blood sample is tested for the
hemochromatosis (HC) gene to determine whether each patient has 0, 1, or 2 copies of the HC
mutation.
Serum hepatitis C virus (HCV) antibody and HCV RNA are measured. Standard liver function
tests and liver biopsy are done if clinically indicated.
A fasting blood level of ascorbic acid is obtained. Blood clearance of caffeine and
antipyrine, and urinary excretion of caffeine and chlorzoxazone metabolites are determined
by breath tests or measurements in blood or saliva.
Genotyping for polymorphic genes for enzymes that metabolize foreign chemicals, including
cytochrome P450 enzymes (CYP) and glutathione transferases are completed.
Following completion of the above studies, patients undergo individualized standard
treatment either by serial phlebotomies or low dose chloroquine. Patients with HCV are also
treated with interferon alfa-2b.
Patients are followed after treatment, at which time initial studies are repeated.
;
Primary Purpose: Screening
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03118674 -
Harvoni Treatment Porphyria Cutanea Tarda
|
Phase 2 | |
| Completed |
NCT00213772 -
Risk Factors of Porphyria Cutanea Tarda (PCT)
|
N/A | |
| Completed |
NCT01573754 -
Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda
|
Phase 2 | |
| Recruiting |
NCT01284946 -
Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda
|
Phase 2 | |
| Completed |
NCT00599326 -
Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda
|
Phase 3 |